Comparative Effectiveness of Ustekinumab Versus Vedolizumab in Treating Crohn's Disease After Failure of Anti-TNF Agents: Real-World Evidence

被引：0
|
作者：
Alamer, A. [1 ]
Al Lehaibi, L. [2 ]
Alomar, M. [2 ]
Aldhuwayan, F. [2 ]
Alshouish, S. [2 ]
Al-Ali, A. [3 ]
Almudhry, Z. [4 ]
Almulhim, A. [5 ]
Althagafi, A. [6 ]
Aldosari, S. [7 ]
Alameel, T. [8 ]
机构：
[1] Prince Sattam Bin Abdulaziz Univ, Dept Clin Pharm, Alkharj, Saudi Arabia
[2] Eastern Hlth Cluster Dammam Med Complex, Dept Clin Pharm, Dammam, Saudi Arabia
[3] Eastern Hlth Cluster Dhahran Eye Specialist Hosp, Dept Clin Pharm, Dhahran, Saudi Arabia
[4] Eastern Hlth Cluster Dammam Med Complex, Dept Med, Dammam, Saudi Arabia
[5] King Faisal Univ, Dept Pharm Practice, Coll Clin Pharm, Alhofuf, Saudi Arabia
[6] King Abdulaziz Univ, Dept Pharm Practice, Fac Pharm, Jeddah, Saudi Arabia
[7] Prince Sattam Bin Abdulaziz Univ, Dept Clin Pharm, Coll Pharm, Alkharj, Saudi Arabia
[8] King Fahad Specialist Hosp Dammam, Dept Med, Dammam, Saudi Arabia
来源：
JOURNAL OF CROHNS & COLITIS | 2024年 / 18卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P688
引用
收藏
页码：I1297 / I1297
页数：1
相关论文
共 50 条
  • [1] Ustekinumab or Vedolizumab after Failure of Anti-TNF Agents in Crohn's Disease: A Review of Comparative Effectiveness Studies
    Sharip, Mohmmed Tauseef
    Nishad, Nilanga
    Pillay, Lushen
    Goordoyel, Nilkantsingh
    Goerge, Samuel
    Subramanian, Sreedhar
    JOURNAL OF CLINICAL MEDICINE, 2024, 13 (08)
  • [2] Comparative Effectiveness of Vedolizumab Versus Ustekinumab in Anti-TNF Experienced Patients With Crohn's Disease
    Kappelman, Michael
    Lewis, James D.
    Zhang, Xian
    Lin, Feng-Chang
    Weisbein, Laura
    Chen, Wenli
    Burris, Jessica L.
    Dorand, Jennifer E.
    Parlett, Lauren E.
    Haynes, Kevin
    Nair, Vinit
    Kaul, Alan F.
    Dobes, Angela
    Long, Millie
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2022, 117 (10): : S676 - S676
  • [3] Real World Evidence Comparing Vedolizumab and Ustekinumab in Anti-TNF Experienced Patients With Crohn's Disease
    Kappelman, Michael
    Adimadhyam, Sruthi
    Hou, Laura
    Simon, Andrew L.
    Dobes, Angela
    Parlett, Lauren E.
    Haynes, Kevin
    Selvan, Mano
    Ma, Qianli
    Nair, Vinit
    Burris, Jessica L.
    Dorand, Jennifer E.
    Long, Millie
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2022, 117 (10): : S519 - S520
  • [4] Comparative study of the effectiveness of vedolizumab versus ustekinumab after anti-TNF failure (VERSUS-CD)
    Garcia, M. J.
    Rivero, M.
    Fernandez-Clotet, A.
    de Francisco, R.
    Sicilia, B.
    Mesonero, F.
    de Castro, M. L.
    Casanova, M. J.
    Bertoletti, F.
    Garcia Alonso, F. J.
    Lopez Garcia, A.
    Julian, B.
    Calvet, X.
    Barreiro-de Acosta, M.
    Jara, L.
    Varela, P.
    Nunez, A.
    Ricart, E.
    Riestra, S.
    Arias, L.
    Rodriguez, M.
    Arranz, L.
    Pajares, R.
    Mena, R.
    Calafat, M.
    Camo, P.
    Jimenez, L.
    Ponferrada, A.
    Madrigal, R. E.
    Llao, J.
    Sese, E.
    Almela, P.
    Codesido, L.
    de la Maza, S.
    Leal, C.
    Sanchez, E.
    Pineda Marino, J. R.
    Domenech, E.
    Chaparro, M.
    Gisbert, J. P.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I121 - I123
  • [5] Comparative Study of the Effectiveness of Vedolizumab Versus Ustekinumab After Anti-TNF Failure in Crohn's Disease (Versus-CD): Data from the ENEIDA Registry
    Jose Garcia, Maria
    Rivero, Montserrat
    Fernandez-Clotet, Agnes
    de Francisco, Ruth
    Sicilia, Beatriz
    Mesonero, Francisco
    Luisa de Castro, Maria
    Jose Casanova, Maria
    Bertoletti, Federico
    Javier Garcia-Alonso, Francisco
    Lopez-Garcia, Alicia
    Vicente, Raquel
    Calvet, Xavier
    Barreiro-de Acosta, Manuel
    Ferrer Rosique, Juan
    Varela Trastoy, Pilar
    Nunez, Alejandro
    Ricart, Elena
    Riestra, Sabino
    Arias Garcia, Lara
    Rodriguez, Maria
    Arranz, Laura
    Pajares, Ramon
    Mena, Raquel
    Calafat, Margalida
    Camo, Patricia
    Bermejo, Fernando
    Ponferrada, Angel
    Eva Madrigal, Rosa
    Llao, Jordina
    Sese, Eva
    Sanchez, Eugenia
    Pineda Marino, Juan Ramon
    Gonzalez Munoza, Carlos
    Carbajo Lopez, Ana Yaiza
    Belen Julian, Ana
    Villoria Ferrer, Albert
    Baston-Rey, Iria
    Jara, Lorena
    Almela, Pedro
    Codesido, Laura
    de la Maza, Saioa
    Leal, Carles
    Caballol, Berta
    Perez-Martinez, Isabel
    Vinuesa Campo, Raquel
    Crespo, Javier
    Domenech, Eugeni
    Chaparro, Maria
    Gisbert, Javier P.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 (01): : 65 - 74
  • [6] Crohn's disease: vedolizumab vs. ustekinumab after anti-TNF pretreatment
    Simon, Annika
    ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2023, 61 (09): : 1168 - 1170
  • [7] Effectiveness of ustekinumab after vedolizumab failure in patients with anti-TNF-refractory Crohn's disease
    Dussias, N.
    Rizzello, F.
    Calabrese, C.
    Passino, A. Sanna
    Melotti, L.
    Scaioli, E.
    Belluzzi, A.
    Gionchetti, P.
    JOURNAL OF CROHNS & COLITIS, 2021, 15 : S528 - S528
  • [8] Letter: effectiveness of ustekinumab or vedolizumab in Crohn's disease following anti-TNF failure-getting closer to the truth?
    Liu, Kecheng
    Cai, Fuqing
    Huang, Jiean
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2020, 52 (07) : 1253 - 1254
  • [9] MULTI-CENTRE COMPARATIVE EFFECTIVENESS OF VEDOLIZUMAB AND USTEKINUMAB AS INDUCTION THERAPY IN ANTI-TNF REFRACTORY CROHN'S DISEASE
    Razanskaite, Violeta
    Michail, Stephanie
    Morgan, James
    Davies, Michael
    Storey, Daneil
    Watters, Christopher
    Penman, Douglas
    Swaminathan, Mira
    Sabine, Joseph
    Chapman, Adam
    Reilly, Ian
    Flanagan, Paul
    Bodger, Keith
    Subramanian, Sreedhar
    GUT, 2019, 68 : A100 - A100
  • [10] Real-world effectiveness and safety of ustekinumab and vedolizumab in elderly patients with Crohn’s disease
    Rajat Garg
    Manik Aggarwal
    Abdul Mohammed
    Jean Paul Achkar
    Bret Lashner
    Jessica Philpott
    Benjamin Cohen
    Taha Qazi
    Florian Rieder
    Miguel Regueiro
    Benjamin Click
    Indian Journal of Gastroenterology, 2023, 42 : 718 - 723
12345